L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · see citing works

Heat Shock Protein A12B Protects Vascular Endothelial Cells Against Sepsis-Induced Acute Lung Injury in Mice

Chen, Y., Wang, L., Kang, Q., Zhang, X., Yu, G., Wan, X., Wang, J., & Zhu, K. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477308 · Cited by 10,730 · see citing works

Alzheimer's Disease: Genes, Proteins, and Therapy

Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063 · see citing works

Mutation of the mouse klotho gene leads to a syndrome resembling ageing

Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837 · see citing works

Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective

Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849 · see citing works

Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial

Forette, F., Seux, M.-L., Staessen, J. A., Thijs, L., Birkenhäger, W. H., Babarskiene, M.-R., Babeanu, S., Bossini, A., Gil-Extremera, B., Girerd, X., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03086-4 · Cited by 1,441 · see citing works

Intraneuronal Aβ Causes the Onset of Early Alzheimer’s Disease-Related Cognitive Deficits in Transgenic Mice

Billings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., & LaFerla, F. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.040 · Cited by 1,294 · see citing works

Soluble Oligomers of Amyloid β Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate Uptake

Li, S., Hong, S., Shepardson, N. E., Walsh, D. M., Shankar, G. M., & Selkoe, D. (2009) · Neuron · doi:10.1016/j.neuron.2009.05.012 · Cited by 972 · see citing works

Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease

Bezprozvanny, I., & Mattson, M. P. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.005 · Cited by 938 · see citing works

Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum.

Arispe, N. J., Rojas, E., & Pollard, H. B. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.567 · Cited by 921 · see citing works

‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease

Chan, C. S., Guzmán, J. N., Ilijić, E., Mercer, J. N., Rick, C., Tkatch, T., Meredith, G. E., & Surmeier, D. J. (2007) · Nature · doi:10.1038/nature05865 · Cited by 905 · see citing works

Cell Death Independent of Caspases: A Review

Bröker, L. E., Kruyt, F. A. E., & Giaccone, G. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2223 · Cited by 899 · see citing works

Toward a Comprehensive Theory for Alzheimer's Disease. Hypothesis: Alzheimer's Disease Is Caused by the Cerebral Accumulation and Cytotoxicity of Amyloid β‐Protein

Selkoe, D. J. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05554.x · Cited by 627 · see citing works

Alzheimer Disease: Mechanistic Understanding Predicts Novel Therapies

Selkoe, D. J. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-8-200404200-00047 · Cited by 381 · see citing works

Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia

Sondag, C. M., Dhawan, G., & Combs, C. K. (2009) · Journal of Neuroinflammation · doi:10.1186/1742-2094-6-1 · Cited by 295 · see citing works

Nimodipine for primary degenerative, mixed and vascular dementia

Birks, J., & López-Arrieta, J. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000147 · Cited by 231 · see citing works

Memantine Improves Cognition and Reduces Alzheimer’s-Like Neuropathology in Transgenic Mice

Martínez‐Coria, H., Green, K. N., Billings, L. M., Kitazawa, M., Albrecht, M., Rammes, G., Parsons, C. G., Gupta, S., Banerjee, P., & LaFerla, F. M. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090452 · Cited by 218 · see citing works

Expression and 1,4-Dihydropyridine-Binding Properties of Brain L-Type Calcium Channel Isoforms

Sinnegger-Brauns, M. J., Huber, I. G., Koschak, A., Wild, C., Obermair, G. J., Einzinger, U., Hoda, J., Sartori, S. B., & Striessnig, J. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.049981 · Cited by 214 · see citing works

β-Amyloid impairs axonal BDNF retrograde trafficking

Poon, W. W., Blurton-Jones, M. M., Tu, C. H., Feinberg, L. M., Chabrier, M. A., Harris, J. W., Jeon, N. L., & Cotman, C. W. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.05.012 · Cited by 198 · see citing works

Chronic dietary α-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice

Quinn, J. F., Bussiere, J. R., Hammond, R., Montine, T. J., Henson, E., Jones, R. E., & Stackman, R. W. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.12.014 · Cited by 160 · see citing works

Alzheimer's-associated Aβ oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal

Pitt, J., Roth, W., Lacor, P., Smith, A. B., Blankenship, M., Velasco, P., De Felice, F., Breslin, P., & Klein, W. L. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.07.018 · Cited by 134 · see citing works

Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia

Tollefson, G. D. (1990) · Biological Psychiatry · doi:10.1016/0006-3223(90)90050-c · Cited by 121 · see citing works

Evaluation of Coenzyme Q as an Antioxidant Strategy for Alzheimer's Disease

Wadsworth, T. L., Bishop, J. A., Pappu, A. S., Woltjer, R. L., & Quinn, J. F. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14210 · Cited by 97 · see citing works

Aβ Oligomers and Fibrillar Aggregates Induce Different Apoptotic Pathways in LAN5 Neuroblastoma Cell Cultures

Picone, P., Carrotta, R., Montana, G., Nobile, M. R., Biagio, P. L. S., & Carlo, M. D. (2009) · Biophysical Journal · doi:10.1016/j.bpj.2008.11.056 · Cited by 97 · see citing works

A New Hypothesis for the Mechanism of Amyloid Toxicity, Based on the Calcium Channel Activity of Amyloid β Protein (AβP) in Phospholipid Bilayer Membranes

Pollard, H. B., Rojas, E., & Arispe, N. J. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb23046.x · Cited by 95 · see citing works

A novel tricyclic pyrone compound ameliorates cell death associated with intracellular amyloid‐β oligomeric complexes

Maezawa, I., Hong, H., Wu, H., Battina, S. K., Rana, S., Iwamoto, T., Radke, G. A., Pettersson, E., Martin, G. M., Hua, D. H., et al. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03862.x · Cited by 88 · see citing works

Resveratrol prevents antibody-induced apoptotic death of retinal cells through upregulation of Sirt1 and Ku70

Anekonda, T. S., & Adamus, G. (2008) · BMC Research Notes · doi:10.1186/1756-0500-1-122 · Cited by 88 · see citing works

Epigallocatechin gallate (EGCG) suppresses β-amyloid-induced neurotoxicity through inhibiting c-Abl/FE65 nuclear translocation and GSK3β activation

Lin, C., Chen, T., Chiu, M., Way, T., & Lin, J. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.05.012 · Cited by 86 · see citing works

Cytotoxicity mediated by conditional expression of a carboxyl-terminal derivative of the β-amyloid precursor protein

Sopher, B. L., Fukuchi, K.-I., Smith, A. C., Leppig, K. A., Furlong, C. E., & Martin, G. M. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90092-2 · Cited by 84 · see citing works

Neurodegenerative mechanisms in alzheimer disease

Sopher, B. L., Fukuchi, K., Kavanagh, T. J., Furlong, C. E., & Martin, G. M. (1996) · Molecular and Chemical Neuropathology · doi:10.1007/bf02814999 · Cited by 75 · see citing works

Combining the rapid MTT formazan exocytosis assay and the MC65 protection assay led to the discovery of carbazole analogs as small molecule inhibitors of Aβ oligomer-induced cytotoxicity

Hong, H., Maezawa, I., Yao, N., Xu, B., Díaz-Avalos, R., Rana, S., Hua, D. H., Cheng, R. H., Lam, K. S., & Jin, L. (2006) · Brain Research · doi:10.1016/j.brainres.2006.10.093 · Cited by 60 · see citing works

Alzheimer’s amyloid peptides mediate hypoxic up‐regulation of L‐type Ca 2+ channels

Scragg, J. L., Fearon, I. M., Boyle, J. P., Ball, S. G., Váradi, G., & Peers, C. (2004) · The FASEB Journal · doi:10.1096/fj.04-2659fje · Cited by 58 · see citing works

Role of glutathione in intracellular amyloid‐α precursor protein/carboxy‐terminal fragment aggregation and associated cytotoxicity

Woltjer, R. L., Nghiem, W., Maezawa, I., Milatović, D., Vaisar, T., Montine, K. S., & Montine, T. J. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03109.x · Cited by 58 · see citing works

l-type calcium channels in the hippocampus and cerebellum of Alzheimer’s disease brain tissue

Coon, A. L., Wallace, D. R., Mactutus, C. F., & Booze, R. M. (1999) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00068-8 · Cited by 54 · see citing works

Proteomic determination of widespread detergent insolubility, including Aβ but not tau, early in the pathogenesis of Alzheimer's disease

Woltjer, R. L., Cimino, P. J., Boutté, A. M., Schantz, A. M., Montine, K. S., Larson, E. B., Bird, T. D., Quinn, J. F., Zhang, J., & Montine, T. J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4263fje · Cited by 49 · see citing works

Novel tricyclic pyrone compounds prevent intracellular APP C99-induced cell death

Jin, L., Hua, D. H., Shie, F., Maezawa, I., Sopher, B. L., & Martin, G. M. (2002) · Journal of Molecular Neuroscience · doi:10.1007/s12031-002-0011-9 · Cited by 46 · see citing works

Clinical findings with nimodipine in dementia: test of the calcium hypothesis.

Fritze, J., & Walden, J. (1995) · PubMed · Cited by 45 · see citing works

Isradipine antagonizes hypobaric hypoxia induced CA1 damage and memory impairment: Complementary roles of L-type calcium channel and NMDA receptors

Barhwal, K. K., Hota, S. K., Baitharu, I., Prasad, D. N., Singh, S. B., & Ilavazhagan, G. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.01.008 · Cited by 43 · see citing works

Effects of chemical chaperones on oxidative stress and detergent-insoluble species formation following conditional expression of amyloid precursor protein carboxy-terminal fragment

Woltjer, R. L., McMahan, W., Milatović, D., Kjerulf, J. D., Shie, F., Rung, L. G., Montine, K. S., & Montine, T. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.10.003 · Cited by 38 · see citing works

Quantification of isradipine in human plasma using LC–MS/MS for pharmacokinetic and bioequivalence study

Park, J., Park, Y., Rhim, S., Jhee, O., Kim, S., Yang, S.-C., Lee, M., Shaw, L. M. J., & Kang, J. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2008.11.021 · Cited by 23 · see citing works

Nimodipine selectively stimulates β-amyloid 1–42 secretion by a mechanism independent of calcium influx blockage

Facchinetti, F., Fasolato, C., DELGIUDICE, E., Burgo, A., Furegato, S., Fusco, M., Basso, E., Seraglia, R., D'Arrigo, A. M., & Leon, A.-S. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.02.006 · Cited by 23 · see citing works

Homing in on Intracellular Aβ?

Golde, T. E., & Janus, C. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.013 · Cited by 23 · see citing works

Application of Coomassie brilliant blue staining to cultured hepatocytes

MOCHIZUKI, Y., & Furukawa, K. (1987) · Cell Biology International Reports · doi:10.1016/0309-1651(87)90003-8 · Cited by 20 · see citing works

Calcium channel blockers and Parkinson disease

Pfeiffer, R. F. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.31 · Cited by 18 · see citing works

Subcutaneous administration of nimodipine improves bioavailability in rabbits

Laslo, A. M., Eastwood, J. D., Urquhart, B. L., Lee, T., & Freeman, D. (2004) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2004.04.030 · Cited by 14 · see citing works

Carboxyl-terminal fragment of amyloid precursor protein and hydrogen peroxide induce neuronal cell death through different pathways

Sebastià, J., Pertusa, M., Vı́lchez, D., Planas, A. M., Verbeek, R., Rodrı́guez-Farré, E., Cristòfol, R. M., & Sanfeliu, C. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0492-8 · Cited by 14 · see citing works

Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development

Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965 · see citing works

Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.

Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138 · see citing works

Drug repositioning for Alzheimer's disease

Corbett, A., Pickett, J., Burns, A. S., Corcoran, J. P. T., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3869 · Cited by 302 · see citing works

The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease

Ilijić, E., Guzmán, J. N., & Surmeier, D. J. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.04.007 · Cited by 260 · see citing works

Calcium signaling in Alzheimer's disease & therapies

Tong, B. C., Wu, A. J., Li, M., & Cheung, K. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.07.018 · Cited by 235 · see citing works

Antimicrobial Properties of Amyloid Peptides

Kagan, B. L., Jang, H., Capone, R. F., Arce, F. T., Ramachandran, S., Lal, R., & Nussinov, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200419b · Cited by 227 · see citing works

Calcium/calmodulin-dependent kinase II and Alzheimer’s disease

Ghosh, A., & Giese, K. P. (2015) · Molecular Brain · doi:10.1186/s13041-015-0166-2 · Cited by 205 · see citing works

Parkinson's Disease Is Not Simply a Prion Disorder

Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1787-16.2017 · Cited by 186 · see citing works

Role of Microglia and Astrocytes in Alzheimer’s Disease: From Neuroinflammation to Ca2+ Homeostasis Dysregulation

Di Benedetto, G., Burgaletto, C., Bellanca, C. M., Munafò, A., Bernardini, R., & Cantarella, G. (2022) · Cells · doi:10.3390/cells11172728 · Cited by 189 · see citing works

Neuronal Store-Operated Calcium Entry and Mushroom Spine Loss in Amyloid Precursor Protein Knock-In Mouse Model of Alzheimer's Disease

Zhang, H., Wu, L., Pchitskaya, E. I., Zakharova, O. A., Saito, T., Saido, T. C., & Борисович, Б. И. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1034-15.2015 · Cited by 181 · see citing works

Calcium channel blockers and dementia

Nimmrich, V., & Eckert, A. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12240 · Cited by 155 · see citing works

A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery

Pillaiyar, T., Meenakshisundaram, S., Manickam, M., & Sankaranarayanan, M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112275 · Cited by 140 · see citing works

Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress

Guzmán, J. N., Ilijić, E., Yang, B., Sánchez-Padilla, J., Wokosin, D. L., Galtieri, D. J., Kondapalli, J., Schumacker, P. T., & Surmeier, D. J. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95898 · Cited by 136 · see citing works

Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: The case for isradipine

Anekonda, T. S., & Quinn, J. F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.08.013 · Cited by 136 · see citing works

Vitamin D and the brain: Key questions for future research

Cui, X., Gooch, H. M., Groves, N. J., Sah, P., Burne, T. H. J., Eyles, D. W., & McGrath, J. J. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.11.004 · Cited by 117 · see citing works

Dysregulation of Intracellular Calcium Signaling in Alzheimer's Disease

Александровна, П. Е., Pchitskaya, E. I., & Борисович, Б. И. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2018.7506 · Cited by 102 · see citing works

Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease

Surmeier, D. J., Halliday, G. M., & Simuni, T. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.08.001 · Cited by 99 · see citing works

Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches

Salahuddin, P., Fatima, M. T., Abdelhameed, A. S., Nusrat, S., & Khan, R. H. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.02.065 · Cited by 95 · see citing works

Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing

Fang, J., Pieper, A. A., Nussinov, R., Lee, G., Bekris, L. M., Leverenz, J. B., Cummings, J. L., & Cheng, F. (2020) · Medicinal Research Reviews · doi:10.1002/med.21709 · Cited by 93 · see citing works

Novel Disease-Modifying Therapies for Alzheimer's Disease

Jiang, T., Yu, J., & Tan, L. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120640 · Cited by 93 · see citing works

Calcium channelopathies and Alzheimer's disease: Insight into therapeutic success and failures

Chakroborty, S., & Stutzmann, G. E. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.012 · Cited by 91 · see citing works

A Review: Treatment of Alzheimer’s Disease Discovered in Repurposed Agents

Appleby, B. S., Nacopoulos, D. A., Milano, N. J., Zhong, K., & Cummings, J. L. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000345791 · Cited by 90 · see citing works

Calcium channel blockers: molecular docking and inhibition studies on carbonic anhydrase I and II isoenzymes

Türkeş, C., Demir, Y., & Beydemir, Ş. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1736631 · Cited by 84 · see citing works

Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer's Disease

Kim, T. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0325-7 · Cited by 82 · see citing works

Anti-diabetic Properties of Calcium Channel Blockers: Inhibition Effects on Aldose Reductase Enzyme Activity

Türkeş, C., Demir, Y., & Beydemir, Ş. (2019) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-019-03009-x · Cited by 83 · see citing works

Role of Calcium Modulation in the Pathophysiology and Treatment of Alzheimer’s Disease

Baracaldo-Santamaría, D., Avendaño-Lopez, S. S., Ariza-Salamanca, D. F., Rodríguez-Giraldo, M., Calderón‐Ospina, C., González-Reyes, R. E., & Nava-Mesa, M. O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109067 · Cited by 85 · see citing works

Discovering New Treatments for Alzheimer's Disease by Repurposing Approved Medications

Appleby, B. S., & Cummings, J. L. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113136660162 · Cited by 78 · see citing works

Micro-RNA-137 Inhibits Tau Hyperphosphorylation in Alzheimer’s Disease and Targets the CACNA1C Gene in Transgenic Mice and Human Neuroblastoma SH-SY5Y Cells

Jiang, Y. Z., Xu, B., Chen, J., Sui, Y., Ren, L., Li, J., Zhang, H., Guo, L., & Sun, X. (2018) · Medical Science Monitor · doi:10.12659/msm.908765 · Cited by 76 · see citing works

Effect of calcium channel blockers on paraoxonase-1 (PON1) activity and oxidative stress

Türkeş, C., Söyüt, H., & Beydemir, Ş. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2013.08.007 · Cited by 74 · see citing works

Resveratrol and Calcium Signaling: Molecular Mechanisms and Clinical Relevance

McCalley, A. E., Kaja, S., Payne, A., & Koulen, P. (2014) · Molecules · doi:10.3390/molecules19067327 · Cited by 74 · see citing works

Calcium Ions in the Physiology and Pathology of the Central Nervous System

Pikor, D., Hurła, M., Słowikowski, B. K., Szymanowicz, O., Poszwa, J., Banaszek, N., Drelichowska, A., Jagodziński, P. P., Kozubski, W. P., & Dorszewska, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313133 · Cited by 75 · see citing works

Association between chronic kidney disease and Alzheimer’s disease: an update

Zhang, C., He, F.-F., Su, H., Zhang, C., & Meng, X. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00561-y · Cited by 70 · see citing works

Pharmacological modulation of septins restores calcium homeostasis and is neuroprotective in models of Alzheimer’s disease

Princen, K., Dooren, T. V., van Gorsel, M., Louros, N. N., Yang, X., Dumbacher, M., Bastiaens, I., Coupet, K., Dupont, S., Cuveliers, E., et al. (2024) · Science · doi:10.1126/science.add6260 · Cited by 71 · see citing works

Effects of Amyloid-β Peptides on Voltage-Gated L-Type CaV1.2 and CaV1.3 Ca2+ Channels

Kim, S., & Rhim, H. (2011) · Molecules and Cells · doi:10.1007/s10059-011-0075-x · Cited by 70 · see citing works

Protective effects of low molecular weight chondroitin sulfate on amyloid beta (Aβ)-induced damage in vitro and in vivo

Zhang, Q., Li, J., Liu, C., Song, C., Li, P., Yin, F., Xiao, Y., Li, J., Jiang, W., Zong, A., et al. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.002 · Cited by 66 · see citing works

Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders

Colbourne, L., & Harrison, P. J. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01615-6 · Cited by 59 · see citing works

Role of GPCR signaling and calcium dysregulation in Alzheimer's disease

Sushma, & Mondal, A. C. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.103414 · Cited by 56 · see citing works

Therapeutic Effect of Agmatine on Neurological Disease: Focus on Ion Channels and Receptors

Barua, S., Kim, J. Y., Kim, J. Y., Kim, J. H., & Lee, J. E. (2019) · Neurochemical Research · doi:10.1007/s11064-018-02712-1 · Cited by 57 · see citing works

Age-related downregulation of the CaV3.1 T-type calcium channel as a mediator of amyloid beta production

Rice, R. A., Berchtold, N. C., Cotman, C. W., & Green, K. N. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.10.090 · Cited by 57 · see citing works

Distinct RGK GTPases Differentially Use α1- and Auxiliary β-Binding-Dependent Mechanisms to Inhibit CaV1.2/CaV2.2 Channels

Yang, T., Puckerin, A., & Colecraft, H. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037079 · Cited by 54 · see citing works

Ca2+ signaling driving pacemaker activity in submucosal interstitial cells of Cajal in the murine colon

Baker, S. A., Leigh, W. A., Valle, G. D., Yturriaga, I. F. D., Ward, S. M., Cobine, C. A., Drumm, B. T., & Sanders, K. M. (2021) · eLife · doi:10.7554/elife.64099 · Cited by 54 · see citing works

Furazans in Medicinal Chemistry

Mancini, R. S., Barden, C., Weaver, D. F., & Reed, M. A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01901 · Cited by 54 · see citing works

Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

Jang, H., Connelly, L. S., Arce, F. T., Ramachandran, S., Lal, R., Kagan, B. L., & Nussinov, R. (2013) · Physical Chemistry Chemical Physics · doi:10.1039/c3cp00017f · Cited by 50 · see citing works

Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease

Corbett, A., Williams, G. H., & Ballard, C. G. (2013) · Pharmaceuticals · doi:10.3390/ph6101304 · Cited by 50 · see citing works

Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease

Chioua, M., Buzzi, E., Moraleda, I., Iriepa, I., Maj, M., Wnorowski, A., Giovannini, C., Tramarin, A., Portali, F., Ismaïli, L., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.06.044 · Cited by 49 · see citing works

Inhibition of β-Amyloid Channels with a Drug Candidate wgx-50 Revealed by Molecular Dynamics Simulations

Hou, S., Gu, R., & Wei, D. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00452 · Cited by 48 · see citing works

Isradipine plasma pharmacokinetics and exposure–response in early Parkinson’s disease

Venuto, C. S., Yang, L., Javidnia, M., Oakes, D., Surmeier, D. J., & Simuni, T. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51300 · Cited by 48 · see citing works

A translational continuum of model systems for evaluating treatment strategies in Alzheimer’s disease: isradipine as a candidate drug

Copenhaver, P. F., Anekonda, T. S., Musashe, D. T., Robinson, K. M., Ramaker, J. M., Swanson, T. L., Wadsworth, T. L., Kretzschmar, D., Woltjer, R. L., & Quinn, J. F. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.006841 · Cited by 44 · see citing works

The Changing Landscape of Voltage-Gated Calcium Channels in Neurovascular Disorders and in Neurodegenerative Diseases

Cataldi, M. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311030004 · Cited by 44 · see citing works

Membrane Pores in the Pathogenesis of Neurodegenerative Disease

Kagan, B. L. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385883-2.00001-1 · Cited by 41 · see citing works

In vivo induction of membrane damage by β-amyloid peptide oligomers

Julien, C., Tomberlin, C., Roberts, C. M., Akram, A., Stein, G. H., Silverman, M. A., & Link, C. D. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0634-x · Cited by 39 · see citing works

Inhibition of ferroptosis through regulating neuronal calcium homeostasis: An emerging therapeutic target for Alzheimer’s disease

Sun, Y., Yan, C., He, L., Xiang, S., Wang, P., Li, Z., Chen, Y., Zhao, J., Yuan, Y., Wang, W., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101899 · Cited by 40 · see citing works

Evolving therapeutic interventions for the management and treatment of Alzheimer’s disease

Ahmad, F., Karan, A., Sharma, R., Sharma, N. S., Sundar, V., Jayaraj, R. L., Mukherjee, S., & DeCoster, M. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102229 · Cited by 38 · see citing works

L-type calcium channel blockade alleviates molecular and reversal spatial learning and memory alterations induced by entorhinal amyloid pathology in rats

Pourbadie, H. G., Naderi, N., Khodagholi, F., Shaerzadeh, F., & Motamedi, F. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.09.045 · Cited by 37 · see citing works

Calcium Dyshomeostasis Drives Pathophysiology and Neuronal Demise in Age-Related Neurodegenerative Diseases

Griffioen, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713243 · Cited by 35 · see citing works

Calcium Signaling in Neurons and Glial Cells: Role of Cav1 channels

Alves, V. S., Alves-Silva, H. S., Orts, D. J. B., Ribeiro-Silva, L., Arcisio-Miranda, M., & Oliveira, F. A. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.09.041 · Cited by 34 · see citing works

Reversal of Calcium Dysregulation as Potential Approach for Treating Alzheimer's Disease

Александровна, П. Е., Chernyuk, D., & Борисович, Б. И. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200528162046 · Cited by 33 · see citing works

Cardiovascular medication burden in dementia disorders: a nationwide study of 19,743 dementia patients in the Swedish Dementia Registry

Čermáková, P., Fereshtehnejad, S., Johnell, K., Winblad, B. G., Eriksdotter, M., & Religa, D. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt264 · Cited by 32 · see citing works

Verapamil and Alzheimer’s Disease: Past, Present, and Future

Popović, N., Morales-Delgado, N., Mena, D. V., Alonso, A., Martínez, M. P., Bleda, M. C., & Popović, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00562 · Cited by 33 · see citing works

Synthesis and studies of calcium channel blocking and antioxidant activities of novel 4-pyridinium and/or N-propargyl substituted 1,4-dihydropyridine derivatives

Ruciņš, M., Kaldre, D., Pajuste, K., Fernandes, M. A. S., Vicente, J. A. F., Klimavičiusa, L., Jaschenko, E., Kanepe, I., Shestakova, I., Plotniece, M., et al. (2013) · Comptes Rendus Chimie · doi:10.1016/j.crci.2013.07.003 · Cited by 32 · see citing works

Carbonic anhydrase activity from the gilthead sea bream (Sparus aurata) liver: The toxicological effects of heavy metals

Kaya, E. D., Söyüt, H., & Beydemir, Ş. (2013) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2013.05.019 · Cited by 32 · see citing works

Interaction between amyloidogenic proteins and biomembranes in protein misfolding diseases: Mechanisms, contributors, and therapy

Cheng, B., Li, Y., Ma, L., Wang, Z., Petersen, R. B., Zheng, L., Chen, Y., & Huang, K. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.02.013 · Cited by 31 · see citing works

Genetic interactions found between calcium channel genes modulate amyloid load measured by positron emission tomography

Koran, M. E. I., Hohman, T. J., & Thornton‐Wells, T. A. (2013) · Human Genetics · doi:10.1007/s00439-013-1354-8 · Cited by 31 · see citing works

Why calcium channel blockers could be an elite choice in the treatment of Alzheimer’s disease: a comprehensive review of evidences

Ponne, S., Chinnadurai, R. K., & Boopathy, R. (2014) · Reviews in the Neurosciences · doi:10.1515/revneuro-2013-0056 · Cited by 31 · see citing works

The Role of Cysteine Protease in Alzheimer Disease

Hasanbašić, S., Jahić, A., Karahmet, E., Sejranic, A., & Prnjavorac, A. (2016) · Materia Socio Medica · doi:10.5455/msm.2016.28.235-238 · Cited by 31 · see citing works

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

Froestl, W., Pfeifer, A., & Muhs, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121729 · Cited by 27 · see citing works

Differential Regulation of N-Methyl-D-Aspartate Receptor Subunits is An Early Event in the Actions of Soluble Amyloid-β1-40 Oligomers on Hippocampal Neurons

Chang, L., Zhang, Y., Liu, J., Song, Y., Lv, A., Li, Y., Zhou, W., Yan, Z., Almeida, O. F. X., & Wu, Y. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150942 · Cited by 27 · see citing works

Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders

Khatri, D. K., Kadbhane, A., Patel, M., Nene, S., Atmakuri, S., Srivastava, S., & Singh, S. B. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100022 · Cited by 24 · see citing works

Low Intensity Electromagnetic Fields Act via Voltage-Gated Calcium Channel (VGCC) Activation to Cause Very Early Onset Alzheimer’s Disease: 18 Distinct Types of Evidence

Pall, M. L. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220202114510 · Cited by 25 · see citing works

Calcium channel blockers and Alzheimer's disease.

Tan, Y., Deng, Y., & Qing, H. (2012) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1673-5374.2012.02.010 · Cited by 25 · see citing works

Calcium signaling hypothesis: A non-negligible pathogenesis in Alzheimer’s disease

Wang, M., Zhang, H., Liang, J., Huang, J., Wu, T., & Chen, N. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.01.007 · Cited by 25 · see citing works

Neuroprotective Effects of Butanol Fraction of Cordyceps cicadae on Glutamate‐Induced Damage in PC12 Cells Involving Oxidative Toxicity

Wang, D., Wang, J., Wang, D., Yu, X., Olatunji, O. J., Ouyang, Z., & Wei, Y. (2017) · Chemistry & Biodiversity · doi:10.1002/cbdv.201700385 · Cited by 24 · see citing works

Current and Future Nano-Carrier-Based Approaches in the Treatment of Alzheimer’s Disease

Kumar, A., Sudevan, S. T., Nair, A. S., Singh, A. K., Kumar, S., Jose, J., Behl, T., Mangalathillam, S., Mathew, B., & Kim, H. (2023) · Brain Sciences · doi:10.3390/brainsci13020213 · Cited by 24 · see citing works

Applications of calcium channel blockers in psychiatry: pharmacokinetic and pharmacodynamic aspects of treatment of bipolar disorder

Dubovsky, S. L. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1558206 · Cited by 24 · see citing works

Unraveling Aβ-Mediated Multi-Pathway Calcium Dynamics in Astrocytes: Implications for Alzheimer’s Disease Treatment From Simulations

Liu, L., Gao, H., Zaikin, A. A., & Chen, S. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.767892 · Cited by 23 · see citing works

In vitro detection of cardiotoxins or neurotoxins affecting ion channels or pumps using beating cardiomyocytes as alternative for animal testing

Nicolas, J., Hendriksen, P. J. M., de Haan, L. H. J., Koning, R., Rietjens, I. M. C. M., & Bovee, T. F. H. (2014) · Toxicology in Vitro · doi:10.1016/j.tiv.2014.11.010 · Cited by 22 · see citing works

A novel acetylcholinesterase inhibitor and calcium channel blocker SCR-1693 improves Aβ25–35-impaired mouse cognitive function

Zhang, Z., Chen, R., An, W., Wang, C., Liao, G., Dong, X., Bi, A., Yin, Z., & Luo, L. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4133-5 · Cited by 21 · see citing works

The Bradykinin B2 Receptor Agonist (NG291) Causes Rapid Onset of Transient Blood–Brain Barrier Disruption Without Evidence of Early Brain Injury

Rodríguez-Massó, S. R., Erickson, M. A., Banks, W. A., Ulrich, H., & Martins, A. H. B. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.791709 · Cited by 21 · see citing works

Role of metal ions in the cognitive decline of Down syndrome

Malakooti, N., Pritchard, M. A., Adlard, P. A., & Finkelstein, D. I. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00136 · Cited by 21 · see citing works

Preventing Effect of L-Type Calcium Channel Blockade on Electrophysiological Alterations in Dentate Gyrus Granule Cells Induced by Entorhinal Amyloid Pathology

Pourbadie, H. G., Naderi, N., Mehranfard, N., Janahmadi, M., Khodagholi, F., & Motamedi, F. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117555 · Cited by 21 · see citing works

Morphological connectivity differences in Alzheimer's disease correlate with gene transcription and cell‐type

Yu, H., Ding, Y.-H., Wei, Y.-B., Dyrba, M., Wang, D., Kang, X., Xu, W.-Z., Zhao, K., & Liu, Y. (2023) · Human Brain Mapping · doi:10.1002/hbm.26512 · Cited by 21 · see citing works

Role of STIM1 in neurodegeneration

Pascual-Caro, C., Espinosa-Bermejo, N., Pozo‐Guisado, E., & Martı́n-Romero, F. J. (2018) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v9.i2.16 · Cited by 19 · see citing works

CRMP2-derived peptide ST2-104 (R9-CBD3) protects SH-SY5Y neuroblastoma cells against Aβ25-35-induced neurotoxicity by inhibiting the pCRMP2/NMDAR2B signaling pathway

Ji, Y., Hu, Y., Ren, J., Khanna, R., Yao, Y., Chen, Y., Li, Q., & Sun, L. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.03.005 · Cited by 19 · see citing works

Modifying Rap1-signalling by targeting Pde6δ is neuroprotective in models of Alzheimer’s disease

Dumbacher, M., Dooren, T. V., Princen, K., Witte, K. D., Farinelli, M., Lievens, S., Tavernier, J. H., Dehaen, W., Wera, S., Winderickx, J., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0283-3 · Cited by 18 · see citing works

Single‐microglia transcriptomic transition network‐based prediction and real‐world patient data validation identifies ketorolac as a repurposable drug for Alzheimer's disease

Xu, J., Song, W., Xu, Z., Danziger, M. M., Karavani, E., Zang, C., Chen, X., Li, Y., Paz, I. R., Gohel, D., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14373 · Cited by 17 · see citing works

Restoration of Olfactory Memory in Drosophila Overexpressing Human Alzheimer’s Disease Associated Tau by Manipulation of L-Type Ca2+ Channels

Higham, J. P., Hidalgo, S., Buhl, E., & Hodge, J. J. L. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00409 · Cited by 17 · see citing works

Open and rearranged norbornane derived polycyclic cage molecules as potential neuroprotective agents through attenuation of MPP+- and calcium overload-induced excitotoxicity in neuroblastoma SH-SY5Y cells

Egunlusi, A. O., Malan, S. F., Omoruyi, S. I., Ekpo, O. E., Palchykov, V. A., & Joubert, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112617 · Cited by 17 · see citing works

Raised Activity of L-Type Calcium Channels Renders Neurons Prone to Form Paroxysmal Depolarization Shifts

Rubi, L., Schandl, U., Lagler, M., Geier, P., Spies, D., Gupta, K. D., Boehm, S., & Kubista, H. (2013) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8234-1 · Cited by 17 · see citing works

Modelling the contributions to hyperexcitability in a mouse model of Alzheimer's disease

Mittag, M., Mediavilla, L., Remy, S., Cuntz, H., & Jedlička, P. (2023) · The Journal of Physiology · doi:10.1113/jp283401 · Cited by 19 · see citing works

Mass spectrometry-based proteomics in Chest Medicine, Gerontology, and Nephrology: subgroups omics for personalized medicine

Lin, S.-Y., Hsu, W., Lin, C., & Chen, C. (2014) · Biomedicine · doi:10.7603/s40681-014-0025-y · Cited by 16 · see citing works

Cav1.2 and Cav1.3 L-type calcium channels operate in a similar voltage range but show different coupling to Ca2+-dependent conductances in hippocampal neurons

Hasreiter, J., Goldnagl, L., Böhm, S., & Kubista, H. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00329.2013 · Cited by 16 · see citing works

Calcium channel blockade attenuates abnormal synaptic transmission in the dentate gyrus elicited by entorhinal amyloidopathy

Pourbadie, H. G., Naderi, N., Janahmadi, M., Mehranfard, N., & Motamedi, F. (2016) · Synapse · doi:10.1002/syn.21915 · Cited by 16 · see citing works

Cytosolic peptides encoding CaV1 C-termini downregulate the calcium channel activity-neuritogenesis coupling

Yang, Y., Yu, Z., Geng, J., Liu, M., Liu, N., Li, P., Hong, W., Yue, S., Jiang, H., Ge, H., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03438-1 · Cited by 15 · see citing works

Antagonism of Neuronal Prostaglandin E2 Receptor Subtype 1 Mitigates Amyloid β Neurotoxicity In Vitro

Li, X., Rose, S. E., Montine, K. S., Keene, C. D., & Montine, T. J. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9380-1 · Cited by 15 · see citing works

Monosialotetrahexosylganglioside Promotes Early Aβ42 Oligomer Formation and Maintenance

Zhang, D. Y., Wang, J., Fleeman, R. M., Kuhn, M. K., Swulius, M. T., Proctor, E. A., & Dokholyan, N. V. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00221 · Cited by 14 · see citing works

Role of TPEN in Amyloid-β25–35-Induced Neuronal Damage Correlating with Recovery of Intracellular Zn2+ and Intracellular Ca2+ Overloading

Chen, W., Wang, Y., Wang, H., An, D., Sun, D., Li, P., Zhang, T., Lu, W., & Liu, Y. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03322-x · Cited by 14 · see citing works

L‐type calcium channel blocker ameliorates diabetic encephalopathy by modulating dysregulated calcium homeostasis

Singhal, K., & Sandhir, R. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23478 · Cited by 14 · see citing works

Calcium regulation and Alzheimer's disease

Rapaka, D., Bitra, V. R., Medapati, J. R., & Akula, A. (2014) · Asian Pacific Journal of Tropical Disease · doi:10.1016/s2222-1808(14)60666-6 · Cited by 14 · see citing works

Ionic Mechanism Underlying Rebound Depolarization in Medial Prefrontal Cortex Pyramidal Neurons

Kurowski, P. N., Grzelka, K., & Szulczyk, P. J. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00093 · Cited by 13 · see citing works

Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: The case for isradipine

Anekonda, T. S., & Quinn, J. F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.08.013 · Cited by 136 · see citing works

P1–115: L‐type calcium channel blockers rescue beta‐amyloid‐42–induced neurotoxicity by inhibiting CREB and CDK5 activation

Qing, H., Tan, Y., Ma, H., & Deng, Y. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.337

L‐Type calcium channel antagonist isradipine decreases area of plaque associated dystrophic neurites in 5XFAD mouse model

Wickline, J. L., Smith, S. E., Odfalk, K. F., Shin, R., Sanchez, J. J., Cundey, R., Javors, M. A., Ginsburg, B. C., & Hopp, S. C. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.069368

L-type calcium channel blockade alleviates molecular and reversal spatial learning and memory alterations induced by entorhinal amyloid pathology in rats

Pourbadie, H. G., Naderi, N., Khodagholi, F., Shaerzadeh, F., & Motamedi, F. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.09.045 · Cited by 37 · see citing works

L-type calcium channel antagonist isradipine age-dependently decreases plaque associated dystrophic neurites in 5XFAD mouse model

Wickline, J. L., Smith, S. A., Shin, R., Odfalk, K. F., Sanchez, J., Javors, M. A., Ginsburg, B. C., & Hopp, S. C. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109454 · Cited by 4 · see citing works